Protocol development, validation, and troubleshooting of in-situ fiber optic bathless dissolution system (FODS) for a pharmaceutical drug testing

• Published in: Journal of pharmaceutical and biomedical analysis 2021-02, Vol.195, p.113833-113833, Article 113833
• Main Authors: Chaturvedi, Kaushalendra, Shah, Harsh S., Sardhara, Rusha, Nahar, Kajal, Dave, Rutesh H., Morris, Kenneth R.
• Format: Article
• Language: English
• Subjects: Chlorpheniramine maleate; Fiber optic dissolution system (FODS); Metformin hydrochloride; Method development; Validation; Warfarin sodium
• ISSN: 0731-7085; 1873-264X
• DOI: 10.1016/j.jpba.2020.113833

[Display omitted] •Despite having technical/analytical advantages FODS is not the chosen technique to support pharmaceuticals’ release testing.•Reasons include a lack of systematic approach for dissolution method development validation and troubleshooting of FODS.•Current work provides a systematic approach for the validation and quantitative assessment for FODS.•Current work describes the technical problems which can arise and possible approaches to troubleshoot these issues.•Troubleshooting steps include modifying or changing instrumental, operational, and data analysis techniques. Currently, there is no systematic approach available for the validation, quantitative assessment, and troubleshooting for the in-situ fiber optic/bathless dissolution system (FODS). In this report, a dissolution protocol was developed and validated for a model product, chlorpheniramine maleate (CPM) 4 mg IR tablets. Dissolution runs were conducted at 37 ± 0.2 °C using a USP apparatus II, at 50 rpm in 500 mL of 0.01 N hydrochloric acid. The dissolution system was validated for linearity, accuracy, precision, specificity, and robustness analogously to an HPLC method validation. The linearity determination method was developed using five concentration levels between 25–125 % of the expected concentration, while for accuracy, 80 %, 100 %, and 120 % levels were used, and precision was determined using six runs at the 100 % level. Probe sampling depth, orientation, analytical wavelength, and paddle speed were varied to evaluate the robustness of the system tested. Method equivalence was established by comparing the dissolution results from FODS and the traditional dissolution method using UV spectrophotometry. Based on the statistics generated using the dissolution tests, the results are linear, accurate, precise, and specific. Robustness testing demonstrates that small changes in operating conditions did not significantly change the result. No significant difference in the amount dissolved at Q-timepoint was observed between FODS and traditional testing. Therefore, the FODS is a suitable alternative to traditional dissolution for CPM immediate-release tablets (many other drug products have been tested in the laboratory, and reports are in preparation). Additionally, the current work discusses problems related to media preparation, probe sensitivity, and excipient effects on data collected using FODS. The instrument-specific artifacts and data analysis problems are addressed and tro